Compare SIBN & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIBN | THQ |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.8M | 784.0M |
| IPO Year | 2018 | N/A |
| Metric | SIBN | THQ |
|---|---|---|
| Price | $18.30 | $19.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $23.88 | N/A |
| AVG Volume (30 Days) | ★ 537.1K | 112.0K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.53% |
| EPS Growth | ★ 41.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,301,000.00 | N/A |
| Revenue This Year | $16.95 | N/A |
| Revenue Next Year | $14.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.53 | N/A |
| 52 Week Low | $11.48 | $16.28 |
| 52 Week High | $21.89 | $20.39 |
| Indicator | SIBN | THQ |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 45.95 |
| Support Level | $18.34 | $18.88 |
| Resistance Level | $19.35 | $19.41 |
| Average True Range (ATR) | 0.67 | 0.27 |
| MACD | -0.12 | -0.08 |
| Stochastic Oscillator | 29.02 | 24.21 |
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies. The fund invests in equity and debt securities of public and private healthcare companies believed by the Fund's Adviser to have potential for above-average growth, and may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, provided these securities comprise 10% or less of Managed Assets.